<?xml version="1.0" encoding="UTF-8"?>
<annotations textSource="immunise-health-gov-au_20170626T104650.txt">
    <annotation>
        <mention id="EHOST_Instance_10404" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="8749" end="8862" />
        <spannedText>If an infant did not receive the birth dose within the 1st 7 days of life, catch-up of that dose is not necessary</spannedText>
        <creationDate>Tue Mar 06 08:31:03 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10404">
        <mentionClass id="claim">If an infant did not receive the birth dose within the 1st 7 days of life, catch-up of that dose is not necessary</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10405" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="8864" end="8974" />
        <spannedText>Such infants then only require 3 doses of a hepatitis B-containing vaccine, given at 2, 4 and 6 months of age</spannedText>
        <creationDate>Tue Mar 06 08:31:49 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10405">
        <mentionClass id="claim">Such infants then only require 3 doses of a hepatitis B-containing vaccine, given at 2, 4 and 6 months of age</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10406" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="8976" end="9167" />
        <spannedText>A 3-dose schedule at birth, 1–2 months and 6–18 months of age has been shown to be equally as immunogenic as the recommended Australian schedule above; such schedules are often used overseas</spannedText>
        <creationDate>Tue Mar 06 08:31:57 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10406">
        <mentionClass id="claim">A 3-dose schedule at birth, 1–2 months and 6–18 months of age has been shown to be equally as immunogenic as the recommended Australian schedule above; such schedules are often used overseas</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10407" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="9168" end="9332" />
        <spannedText>30-32 Children born overseas who have received hepatitis B vaccine in such a 3-dose schedule can also be considered to have completed the primary vaccination course</spannedText>
        <creationDate>Tue Mar 06 08:32:11 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10407">
        <mentionClass id="claim">30-32 Children born overseas who have received hepatitis B vaccine in such a 3-dose schedule can also be considered to have completed the primary vaccination course</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10408" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="9334" end="9458" />
        <spannedText>For infants, the final dose of the primary hepatitis B vaccine course should preferably be administered at ≥24 weeks of age</spannedText>
        <creationDate>Tue Mar 06 08:32:19 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10408">
        <mentionClass id="claim">For infants, the final dose of the primary hepatitis B vaccine course should preferably be administered at ≥24 weeks of age</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10409" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="9460" end="9668" />
        <spannedText>However, if the final dose is given at &lt;24 weeks but ≥16 weeks of age, it is not necessary to repeat the dose, provided the minimum intervals between doses in Table 2.1.7 (in 2.1.5ï¿½Catch-up.) have been met</spannedText>
        <creationDate>Tue Mar 06 08:32:33 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10409">
        <mentionClass id="claim">However, if the final dose is given at &lt;24 weeks but ≥16 weeks of age, it is not necessary to repeat the dose, provided the minimum intervals between doses in Table 2.1.7 (in 2.1.5ï¿½Catch-up.) have been met</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10410" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="11952" end="12017" />
        <spannedText>The minimum intervals outlined above should be met where possible</spannedText>
        <creationDate>Tue Mar 06 08:35:49 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10410">
        <mentionClass id="claim">The minimum intervals outlined above should be met where possible</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10411" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="12426" end="12650" />
        <spannedText>The majority of individuals in whom anti-HBs becomes undetectable have been shown to mount an anamnestic response to an additional vaccine dose, which indicates they are likely to be protected if exposed to hepatitis B virus</spannedText>
        <creationDate>Tue Mar 06 08:36:42 MST 2018</creationDate>
    </annotation>
    <complexSlotMention id="EHOST_Instance_10487">
        <mentionSlot id="has_source" />
        <complexSlotMentionValue value="EHOST_Instance_10481" />
    </complexSlotMention>
    <classMention id="EHOST_Instance_10411">
        <hasSlotMention id="EHOST_Instance_10487" />
        <mentionClass id="claim">The majority of individuals in whom anti-HBs becomes undetectable have been shown to mount an anamnestic response to an additional vaccine dose, which indicates they are likely to be protected if exposed to hepatitis B virus</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10412" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="16328" end="16527" />
        <spannedText>Accelerated schedules should only be used for those persons with an imminent risk of exposure, such as those intending to travel to hepatitis B endemic areas with a very limited time before departure</spannedText>
        <creationDate>Tue Mar 06 08:54:37 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10412">
        <mentionClass id="claim">Accelerated schedules should only be used for those persons with an imminent risk of exposure, such as those intending to travel to hepatitis B endemic areas with a very limited time before departure</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10413" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="16961" end="17198" />
        <spannedText>Three-dose schedules for adults and children aged &lt;16 years are acceptable; however, a 2-dose schedule in children 1–15 years of age, using Twinrix (720/20), also results in protective antibody levels for both hepatitis A and hepatitis B</spannedText>
        <creationDate>Tue Mar 06 08:57:26 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10413">
        <mentionClass id="claim">Three-dose schedules for adults and children aged &lt;16 years are acceptable; however, a 2-dose schedule in children 1–15 years of age, using Twinrix (720/20), also results in protective antibody levels for both hepatitis A and hepatitis B</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10414" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="18019" end="18078" />
        <spannedText>Reconstituted vaccine should be used as soon as practicable</spannedText>
        <creationDate>Tue Mar 06 08:57:56 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10414">
        <mentionClass id="claim">Reconstituted vaccine should be used as soon as practicable</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10415" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="17872" end="18017" />
        <spannedText>Infanrix hexa must be reconstituted by adding the entire contents of the syringe to the vial and shaking until the pellet is completely dissolved</spannedText>
        <creationDate>Tue Mar 06 08:58:06 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10415">
        <mentionClass id="claim">Infanrix hexa must be reconstituted by adding the entire contents of the syringe to the vial and shaking until the pellet is completely dissolved</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10416" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="21127" end="21238" />
        <spannedText>The birth dose should be given as soon as the baby is medically stable, and preferably within 24 hours of birth</spannedText>
        <creationDate>Tue Mar 06 09:08:09 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10416">
        <mentionClass id="claim">The birth dose should be given as soon as the baby is medically stable, and preferably within 24 hours of birth</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10417" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="20664" end="21123" />
        <spannedText>The rationale for recommending the birth dose for all newborn infants is not only to prevent vertical transmission from a mother with chronic hepatitis B infection (recognising that there may be errors or delays in maternal testing, reporting, communication or appropriate response), but also to prevent horizontal transmission to the infant in the first months of life from persons with chronic hepatitis B infection who are household or other close contacts</spannedText>
        <creationDate>Tue Mar 06 09:08:21 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10417">
        <mentionClass id="claim">The rationale for recommending the birth dose for all newborn infants is not only to prevent vertical transmission from a mother with chronic hepatitis B infection (recognising that there may be errors or delays in maternal testing, reporting, communication or appropriate response), but also to prevent horizontal transmission to the infant in the first months of life from persons with chronic hepatitis B infection who are household or other close contacts</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10418" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="21240" end="21355" />
        <spannedText>Every effort should be made to administer the vaccine before discharge from the obstetric hospital or delivery unit</spannedText>
        <creationDate>Tue Mar 06 09:08:30 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10418">
        <mentionClass id="claim">Every effort should be made to administer the vaccine before discharge from the obstetric hospital or delivery unit</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10419" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="21357" end="21592" />
        <spannedText>All newborns of mothers known to have chronic hepatitis B infection must be given a birth dose of hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) (refer to ‘Management of infants born to mothers who are HBsAg-positive’ below)</spannedText>
        <creationDate>Tue Mar 06 09:08:37 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10419">
        <mentionClass id="claim">All newborns of mothers known to have chronic hepatitis B infection must be given a birth dose of hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) (refer to ‘Management of infants born to mothers who are HBsAg-positive’ below)</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10420" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="22326" end="22481" />
        <spannedText>Routine antenatal screening of pregnant women for HBsAg is recommended to enable appropriate management to prevent newborn infants developing HBV infection</spannedText>
        <creationDate>Tue Mar 06 09:13:09 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10420">
        <mentionClass id="claim">Routine antenatal screening of pregnant women for HBsAg is recommended to enable appropriate management to prevent newborn infants developing HBV infection</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10421" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="22779" end="22997" />
        <spannedText>Infants born to HBsAg-positive mothers should be given HBIG and a dose of monovalent hepatitis B vaccine on the day of birth, concurrently but in separate thighs. The dose of HBIG is 100 IU, to be given by IM injection</spannedText>
        <creationDate>Tue Mar 06 09:13:29 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10421">
        <mentionClass id="claim">Infants born to HBsAg-positive mothers should be given HBIG and a dose of monovalent hepatitis B vaccine on the day of birth, concurrently but in separate thighs. The dose of HBIG is 100 IU, to be given by IM injection</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10422" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="22999" end="23201" />
        <spannedText>It is preferable to administer HBIG immediately after birth (preferably within 12 hours of birth and certainly within 48 hours) as its efficacy decreases markedly if given more than 48 hours after birth</spannedText>
        <creationDate>Tue Mar 06 09:13:43 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10422">
        <mentionClass id="claim">It is preferable to administer HBIG immediately after birth (preferably within 12 hours of birth and certainly within 48 hours) as its efficacy decreases markedly if given more than 48 hours after birth</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10423" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="23203" end="23341" />
        <spannedText>The dose of monovalent hepatitis B vaccine should be given to the infant preferably within 24 hours of birth, and definitely within 7 days</spannedText>
        <creationDate>Tue Mar 06 09:14:19 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10423">
        <mentionClass id="claim">The dose of monovalent hepatitis B vaccine should be given to the infant preferably within 24 hours of birth, and definitely within 7 days</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10424" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="23463" end="23638" />
        <spannedText>Vaccination should not be delayed beyond 7 days after birth, as vaccination alone has been shown to be reasonably effective in preventing infection, provided it is given early</spannedText>
        <creationDate>Tue Mar 06 09:14:28 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10424">
        <mentionClass id="claim">Vaccination should not be delayed beyond 7 days after birth, as vaccination alone has been shown to be reasonably effective in preventing infection, provided it is given early</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10425" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="23642" end="23828" />
        <spannedText>Three subsequent doses of a hepatitis B-containing vaccine should be given, at 2, 4 and 6 months of age, so that the infant receives a total of 4 doses of hepatitis B-containing vaccines</spannedText>
        <creationDate>Tue Mar 06 09:14:35 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10425">
        <mentionClass id="claim">Three subsequent doses of a hepatitis B-containing vaccine should be given, at 2, 4 and 6 months of age, so that the infant receives a total of 4 doses of hepatitis B-containing vaccines</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10426" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="23830" end="24004" />
        <spannedText>Anti-HBs antibody and HBsAg levels should be measured in infants born to mothers with chronic hepatitis B infection 3 to 12 months after completing the primary vaccine course</spannedText>
        <creationDate>Tue Mar 06 09:14:49 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10426">
        <mentionClass id="claim">Anti-HBs antibody and HBsAg levels should be measured in infants born to mothers with chronic hepatitis B infection 3 to 12 months after completing the primary vaccine course</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10427" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="24006" end="24127" />
        <spannedText>Testing should not be performed before 9 months of age to avoid detection of anti-HBs antibodies from HBIG given at birth</spannedText>
        <creationDate>Tue Mar 06 09:14:56 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10427">
        <mentionClass id="claim">Testing should not be performed before 9 months of age to avoid detection of anti-HBs antibodies from HBIG given at birth</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10428" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="24328" end="24442" />
        <spannedText>If the anti-HBs level is &lt;10 mIU/mL, expert advice regarding revaccination and/or further testing should be sought</spannedText>
        <creationDate>Tue Mar 06 09:15:20 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10428">
        <mentionClass id="claim">If the anti-HBs level is &lt;10 mIU/mL, expert advice regarding revaccination and/or further testing should be sought</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10429" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="24992" end="25086" />
        <spannedText>HIV-positive children should receive 3 doses of hepatitis B vaccine using an adult formulation</spannedText>
        <creationDate>Tue Mar 06 09:15:41 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10429">
        <mentionClass id="claim">HIV-positive children should receive 3 doses of hepatitis B vaccine using an adult formulation</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10430" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="25997" end="26061" />
        <spannedText>vaccination of all children and adolescents should be encouraged</spannedText>
        <creationDate>Tue Mar 06 09:16:11 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10430">
        <mentionClass id="claim">vaccination of all children and adolescents should be encouraged</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10431" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="26403" end="26656" />
        <spannedText>Adolescents who did not receive an age-appropriate completed course of vaccination should be identified and offered catch-up vaccination, particularly if they fall into one of the risk categories for hepatitis B infection, discussed under ‘Adults’ below</spannedText>
        <creationDate>Tue Mar 06 09:16:33 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10431">
        <mentionClass id="claim">Adolescents who did not receive an age-appropriate completed course of vaccination should be identified and offered catch-up vaccination, particularly if they fall into one of the risk categories for hepatitis B infection, discussed under ‘Adults’ below</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10432" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="28173" end="28367" />
        <spannedText>Susceptible sexual partners of persons who are HBsAg-positive should be offered post-exposure HBIG and hepatitis B vaccination; both should be initiated within 14 days of the last sexual contact</spannedText>
        <creationDate>Wed Mar 07 03:59:09 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10432">
        <mentionClass id="claim">Susceptible sexual partners of persons who are HBsAg-positive should be offered post-exposure HBIG and hepatitis B vaccination; both should be initiated within 14 days of the last sexual contact</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10433" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="28449" end="28607" />
        <spannedText>Hepatitis B is relatively common in clients of sexual health services and vaccination should be offered to susceptible persons at the time of first attendance</spannedText>
        <creationDate>Wed Mar 07 04:00:00 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10433">
        <mentionClass id="claim">Hepatitis B is relatively common in clients of sexual health services and vaccination should be offered to susceptible persons at the time of first attendance</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10434" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="28609" end="28684" />
        <spannedText>Susceptible, sexually active men who have sex with men should be vaccinated</spannedText>
        <creationDate>Wed Mar 07 04:00:08 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10434">
        <mentionClass id="claim">Susceptible, sexually active men who have sex with men should be vaccinated</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10435" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="29212" end="29298" />
        <spannedText>Such persons should be offered testing for hepatitis B, and vaccination if appropriate</spannedText>
        <creationDate>Wed Mar 07 04:00:25 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10435">
        <mentionClass id="claim">Such persons should be offered testing for hepatitis B, and vaccination if appropriate</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10436" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="30643" end="30721" />
        <spannedText>These patients should be given a larger than usual dose of hepatitis B vaccine</spannedText>
        <creationDate>Wed Mar 07 04:02:02 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10436">
        <mentionClass id="claim">These patients should be given a larger than usual dose of hepatitis B vaccine</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10437" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="30724" end="30791" />
        <spannedText>Adult haemodialysis or pre-dialysis patients should be given either</spannedText>
        <creationDate>Wed Mar 07 04:02:18 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10437">
        <mentionClass id="claim">Adult haemodialysis or pre-dialysis patients should be given either</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10438" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="30858" end="31042" />
        <spannedText>If seronegative for hepatitis B, solid organ transplant recipients should be vaccinated before transplantation as they may be at increased risk of infection from the transplanted organ</spannedText>
        <creationDate>Wed Mar 07 04:02:47 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10438">
        <mentionClass id="claim">If seronegative for hepatitis B, solid organ transplant recipients should be vaccinated before transplantation as they may be at increased risk of infection from the transplanted organ</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10439" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="31046" end="31219" />
        <spannedText>Haematopoietic stem cell transplant recipients should be revaccinated following transplantation, due to the loss of immune memory that often follows the transplant procedure</spannedText>
        <creationDate>Wed Mar 07 04:03:01 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10439">
        <mentionClass id="claim">Haematopoietic stem cell transplant recipients should be revaccinated following transplantation, due to the loss of immune memory that often follows the transplant procedure</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10440" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="32047" end="32158" />
        <spannedText>Persons who inject drugs should be tested, and be vaccinated if they have not previously been infected with HBV</spannedText>
        <creationDate>Wed Mar 07 04:03:31 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10440">
        <mentionClass id="claim">Persons who inject drugs should be tested, and be vaccinated if they have not previously been infected with HBV</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10441" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="32856" end="33112" />
        <spannedText>persons with clotting disorders who receive blood product concentrates, persons with recurrent transfusion requirements, and persons with underlying immunocompromise68 have an elevated risk of hepatitis B virus infection, and should therefore be vaccinated</spannedText>
        <creationDate>Wed Mar 07 04:04:08 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10441">
        <mentionClass id="claim">persons with clotting disorders who receive blood product concentrates, persons with recurrent transfusion requirements, and persons with underlying immunocompromise68 have an elevated risk of hepatitis B virus infection, and should therefore be vaccinated</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10442" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="33754" end="33938" />
        <spannedText>they should be offered the opportunity to be screened for hepatitis Bupon incarceration, as part of the preventive health program for blood-borne viruses, and vaccinated if susceptible</spannedText>
        <creationDate>Wed Mar 07 04:07:27 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10442">
        <mentionClass id="claim">they should be offered the opportunity to be screened for hepatitis Bupon incarceration, as part of the preventive health program for blood-borne viruses, and vaccinated if susceptible</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10443" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="34413" end="34558" />
        <spannedText>it is recommended that all staff directly involved in patient care and/or the handling of human tissue, blood or body fluids should be vaccinated</spannedText>
        <creationDate>Wed Mar 07 04:07:47 MST 2018</creationDate>
    </annotation>
    <complexSlotMention id="EHOST_Instance_10488">
        <mentionSlot id="has_source" />
        <complexSlotMentionValue value="EHOST_Instance_10483" />
    </complexSlotMention>
    <classMention id="EHOST_Instance_10443">
        <hasSlotMention id="EHOST_Instance_10488" />
        <mentionClass id="claim">it is recommended that all staff directly involved in patient care and/or the handling of human tissue, blood or body fluids should be vaccinated</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10444" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="34573" end="34686" />
        <spannedText>standard precautions against exposure to human tissue, blood or body fluids should be used as a matter of routine</spannedText>
        <creationDate>Wed Mar 07 04:07:54 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10444">
        <mentionClass id="claim">standard precautions against exposure to human tissue, blood or body fluids should be used as a matter of routine</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10445" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="34851" end="34947" />
        <spannedText>If advice on risk is sought, the enquiry should be directed to the local public health authority</spannedText>
        <creationDate>Wed Mar 07 04:08:24 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10445">
        <mentionClass id="claim">If advice on risk is sought, the enquiry should be directed to the local public health authority</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10446" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="35026" end="35080" />
        <spannedText>age-appropriate hepatitis B vaccination is recommended</spannedText>
        <creationDate>Wed Mar 07 04:08:40 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10446">
        <mentionClass id="claim">age-appropriate hepatitis B vaccination is recommended</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10447" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="35122" end="35356" />
        <spannedText>Persons travelling to regions of intermediate or high endemicity, either long-term or for frequent short terms, or who are likely to undertake activities that increase their risks of exposure to HBV during travel, should be vaccinated</spannedText>
        <creationDate>Wed Mar 07 04:08:51 MST 2018</creationDate>
    </annotation>
    <complexSlotMention id="EHOST_Instance_10489">
        <mentionSlot id="has_source" />
        <complexSlotMentionValue value="EHOST_Instance_10484" />
    </complexSlotMention>
    <classMention id="EHOST_Instance_10447">
        <hasSlotMention id="EHOST_Instance_10489" />
        <mentionClass id="claim">Persons travelling to regions of intermediate or high endemicity, either long-term or for frequent short terms, or who are likely to undertake activities that increase their risks of exposure to HBV during travel, should be vaccinated</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10448" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="35496" end="35651" />
        <spannedText>Combination hepatitis A/hepatitis B vaccines should be considered for susceptible persons in whom both hepatitis A and hepatitis B vaccines are recommended</spannedText>
        <creationDate>Wed Mar 07 04:09:00 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10448">
        <mentionClass id="claim">Combination hepatitis A/hepatitis B vaccines should be considered for susceptible persons in whom both hepatitis A and hepatitis B vaccines are recommended</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10449" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="36779" end="36905" />
        <spannedText>The time for boosting in such persons should be decided by regular monitoring of anti-HBs levels at 6- to 12-monthly intervals</spannedText>
        <creationDate>Wed Mar 07 04:10:50 MST 2018</creationDate>
    </annotation>
    <complexSlotMention id="EHOST_Instance_10490">
        <mentionSlot id="has_source" />
        <complexSlotMentionValue value="EHOST_Instance_10485" />
    </complexSlotMention>
    <classMention id="EHOST_Instance_10449">
        <hasSlotMention id="EHOST_Instance_10490" />
        <mentionClass id="claim">The time for boosting in such persons should be decided by regular monitoring of anti-HBs levels at 6- to 12-monthly intervals</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10450" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="37934" end="38090" />
        <spannedText>Testing also identifies those who are susceptible to HBV infection and, as such, should be offered vaccination if they continue to have a high exposure risk</spannedText>
        <creationDate>Wed Mar 07 09:14:20 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10450">
        <mentionClass id="claim">Testing also identifies those who are susceptible to HBV infection and, as such, should be offered vaccination if they continue to have a high exposure risk</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10451" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="38639" end="38813" />
        <spannedText>Anti-HBs antibody and HBsAg levels should be measured in infants born to mothers with chronic hepatitis B infection 3 to 12 months after completing the primary vaccine course</spannedText>
        <creationDate>Wed Mar 07 09:14:50 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10451">
        <mentionClass id="claim">Anti-HBs antibody and HBsAg levels should be measured in infants born to mothers with chronic hepatitis B infection 3 to 12 months after completing the primary vaccine course</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10452" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="39136" end="39437" />
        <spannedText>For these individuals, if adequate anti-HBs levels (≥10 mIU/mL) are not reached on serological testing 4 to 8 weeks after the 3rd dose, the possibility of HBV infection, including chronic HBV infection, should be investigated by testing for serological markers, including HBsAg and anti-HBc antibodies</spannedText>
        <creationDate>Wed Mar 07 09:15:17 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10452">
        <mentionClass id="claim">For these individuals, if adequate anti-HBs levels (≥10 mIU/mL) are not reached on serological testing 4 to 8 weeks after the 3rd dose, the possibility of HBV infection, including chronic HBV infection, should be investigated by testing for serological markers, including HBsAg and anti-HBc antibodies</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10453" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="39439" end="39611" />
        <spannedText>In select cases in which hepatitis B infection is suspected, HBV nucleic acid testing may also be indicated, and expert advice regarding further management should be sought</spannedText>
        <creationDate>Wed Mar 07 09:15:26 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10453">
        <mentionClass id="claim">In select cases in which hepatitis B infection is suspected, HBV nucleic acid testing may also be indicated, and expert advice regarding further management should be sought</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10454" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="39613" end="39733" />
        <spannedText>If there are no markers of HBV infection, the individual should be managed as a non-responder to hepatitis B vaccination</spannedText>
        <creationDate>Wed Mar 07 09:15:32 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10454">
        <mentionClass id="claim">If there are no markers of HBV infection, the individual should be managed as a non-responder to hepatitis B vaccination</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10455" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="39792" end="40039" />
        <spannedText>If persons who are at significant risk of hepatitis B (such as healthcare workers) were not tested for anti-HBs within 4 to 8 weeks after completion of the documented primary course, they should still undergo serological testing to ensure immunity</spannedText>
        <creationDate>Wed Mar 07 09:15:41 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10455">
        <mentionClass id="claim">If persons who are at significant risk of hepatitis B (such as healthcare workers) were not tested for anti-HBs within 4 to 8 weeks after completion of the documented primary course, they should still undergo serological testing to ensure immunity</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10456" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="40166" end="40273" />
        <spannedText>Persons with immune memory established from effective prior vaccination should respond to this booster dose</spannedText>
        <creationDate>Wed Mar 07 09:15:53 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10456">
        <mentionClass id="claim">Persons with immune memory established from effective prior vaccination should respond to this booster dose</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10457" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="40275" end="40418" />
        <spannedText>Anti-HBs should be checked 4 weeks later, and if the anti-HBs level remains &lt;10 mIU/mL, the possibility of HBV infection should be investigated</spannedText>
        <creationDate>Wed Mar 07 09:16:04 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10457">
        <mentionClass id="claim">Anti-HBs should be checked 4 weeks later, and if the anti-HBs level remains &lt;10 mIU/mL, the possibility of HBV infection should be investigated</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10458" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="40425" end="40500" />
        <spannedText>if excluded, the person should be managed as a non-responder to vaccination</spannedText>
        <creationDate>Wed Mar 07 09:16:11 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10458">
        <mentionClass id="claim">if excluded, the person should be managed as a non-responder to vaccination</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10459" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="42559" end="42698" />
        <spannedText>Persistent non-responders should be informed that they should be considered not protected against hepatitis B and should minimise exposures</spannedText>
        <creationDate>Wed Mar 07 09:17:55 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10459">
        <mentionClass id="claim">Persistent non-responders should be informed that they should be considered not protected against hepatitis B and should minimise exposures</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10460" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="42699" end="42809" />
        <spannedText>They should also be informed about the need for HBIG within 72 hours of parenteral or mucosal exposure to HBV</spannedText>
        <creationDate>Wed Mar 07 09:18:03 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10460">
        <mentionClass id="claim">They should also be informed about the need for HBIG within 72 hours of parenteral or mucosal exposure to HBV</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10461" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="44216" end="44414" />
        <spannedText>Although various adverse events such as demyelinating diseases, Guillain-Barrï¿½ syndrome and arthritis have been reported, there is no evidence of a causal relationship with hepatitis B vaccination</spannedText>
        <creationDate>Wed Mar 07 09:19:47 MST 2018</creationDate>
    </annotation>
    <complexSlotMention id="EHOST_Instance_10491">
        <mentionSlot id="has_source" />
        <complexSlotMentionValue value="EHOST_Instance_10486" />
    </complexSlotMention>
    <classMention id="EHOST_Instance_10461">
        <hasSlotMention id="EHOST_Instance_10491" />
        <mentionClass id="claim">Although various adverse events such as demyelinating diseases, Guillain-Barrï¿½ syndrome and arthritis have been reported, there is no evidence of a causal relationship with hepatitis B vaccination</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10462" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="44564" end="44640" />
        <spannedText>there is no link between MS [multiple sclerosis] and hepatitis B vaccination</spannedText>
        <creationDate>Wed Mar 07 09:20:19 MST 2018</creationDate>
    </annotation>
    <complexSlotMention id="EHOST_Instance_10492">
        <mentionSlot id="has_source" />
        <complexSlotMentionValue value="EHOST_Instance_10467" />
    </complexSlotMention>
    <classMention id="EHOST_Instance_10462">
        <hasSlotMention id="EHOST_Instance_10492" />
        <mentionClass id="claim">there is no link between MS [multiple sclerosis] and hepatitis B vaccination</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10463" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="45050" end="45300" />
        <spannedText>Further instructions about the public health management of hepatitis B, including management of cases of acute hepatitis B and newly identified chronic hepatitis B, and their contacts, should be obtained from state/territory public health authorities</spannedText>
        <creationDate>Wed Mar 07 09:20:43 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10463">
        <mentionClass id="claim">Further instructions about the public health management of hepatitis B, including management of cases of acute hepatitis B and newly identified chronic hepatitis B, and their contacts, should be obtained from state/territory public health authorities</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10464" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="45440" end="45655" />
        <spannedText>Following significant exposure (percutaneous, ocular or mucous membrane) to blood or to potentially blood-contaminated secretions, where feasible, the source individual should be tested for HBsAg as soon as possible</spannedText>
        <creationDate>Wed Mar 07 09:20:53 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10464">
        <mentionClass id="claim">Following significant exposure (percutaneous, ocular or mucous membrane) to blood or to potentially blood-contaminated secretions, where feasible, the source individual should be tested for HBsAg as soon as possible</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10465" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="45657" end="45820" />
        <spannedText>If the person exposed has not been previously vaccinated against hepatitis B, their anti-HBs level, and anti-HBc and HBsAg status, should be determined immediately</spannedText>
        <creationDate>Wed Mar 07 09:20:59 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10465">
        <mentionClass id="claim">If the person exposed has not been previously vaccinated against hepatitis B, their anti-HBs level, and anti-HBc and HBsAg status, should be determined immediately</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10466" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="45822" end="46019" />
        <spannedText>If the person exposed is anti-HBs and anti-HBc negative (non-immune) and the source is either HBsAg-positive or cannot be identified and tested rapidly, a single dose of HBIG should be administered</spannedText>
        <creationDate>Wed Mar 07 09:21:14 MST 2018</creationDate>
    </annotation>
    <complexSlotMention id="EHOST_Instance_10493">
        <mentionSlot id="has_source" />
        <complexSlotMentionValue value="EHOST_Instance_10468" />
    </complexSlotMention>
    <classMention id="EHOST_Instance_10466">
        <hasSlotMention id="EHOST_Instance_10493" />
        <mentionClass id="claim">If the person exposed is anti-HBs and anti-HBc negative (non-immune) and the source is either HBsAg-positive or cannot be identified and tested rapidly, a single dose of HBIG should be administered</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10467" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="44509" end="44543" />
        <spannedText>multiple studies and review panels</spannedText>
        <creationDate>Wed Mar 07 09:21:31 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10467">
        <mentionClass id="source_of_claim">multiple studies and review panels</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10468" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="46033" end="46068" />
        <spannedText>the recommendations in Table 4.5.3.</spannedText>
        <creationDate>Wed Mar 07 09:23:23 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10468">
        <mentionClass id="source_of_claim">the recommendations in Table 4.5.3.</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10469" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="46187" end="46244" />
        <spannedText>Hepatitis Bvaccine must also be given as soon as possible</spannedText>
        <creationDate>Wed Mar 07 09:22:07 MST 2018</creationDate>
    </annotation>
    <complexSlotMention id="EHOST_Instance_10494">
        <mentionSlot id="has_source" />
        <complexSlotMentionValue value="EHOST_Instance_10470" />
    </complexSlotMention>
    <classMention id="EHOST_Instance_10469">
        <hasSlotMention id="EHOST_Instance_10494" />
        <mentionClass id="claim">Hepatitis Bvaccine must also be given as soon as possible</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10470" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="46283" end="46295" />
        <spannedText>Table 4.5.3.</spannedText>
        <creationDate>Wed Mar 07 09:23:18 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10470">
        <mentionClass id="source_of_claim">Table 4.5.3.</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10471" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="46588" end="46702" />
        <spannedText>If the response to previous vaccination is unknown, the anti-HBs level should be determined as quickly as possible</spannedText>
        <creationDate>Wed Mar 07 09:22:43 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10471">
        <mentionClass id="claim">If the response to previous vaccination is unknown, the anti-HBs level should be determined as quickly as possible</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10472" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="46704" end="46826" />
        <spannedText>If the anti-HBs level is &lt;10 mIU/mL and there is no evidence of HBV infection, HBIG and HBV vaccine should be administered</spannedText>
        <creationDate>Wed Mar 07 09:22:50 MST 2018</creationDate>
    </annotation>
    <complexSlotMention id="EHOST_Instance_10495">
        <mentionSlot id="has_source" />
        <complexSlotMentionValue value="EHOST_Instance_10473" />
    </complexSlotMention>
    <classMention id="EHOST_Instance_10472">
        <hasSlotMention id="EHOST_Instance_10495" />
        <mentionClass id="claim">If the anti-HBs level is &lt;10 mIU/mL and there is no evidence of HBV infection, HBIG and HBV vaccine should be administered</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10473" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="46834" end="46846" />
        <spannedText>Table 4.5.3.</spannedText>
        <creationDate>Wed Mar 07 09:23:12 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10473">
        <mentionClass id="source_of_claim">Table 4.5.3.</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10474" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="46854" end="46916" />
        <spannedText>All healthcare workers should be immunised against hepatitis B</spannedText>
        <creationDate>Wed Mar 07 09:23:42 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10474">
        <mentionClass id="claim">All healthcare workers should be immunised against hepatitis B</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10475" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="47711" end="47809" />
        <spannedText>As stocks of HBIG are very limited, use should be strictly reserved for those who are at high risk</spannedText>
        <creationDate>Wed Mar 07 09:24:44 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10475">
        <mentionClass id="claim">As stocks of HBIG are very limited, use should be strictly reserved for those who are at high risk</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10476" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="48094" end="48187" />
        <spannedText>Requests should be directed to the Australian Red Cross Blood Service in your state/territory</spannedText>
        <creationDate>Wed Mar 07 09:24:52 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10476">
        <mentionClass id="claim">Requests should be directed to the Australian Red Cross Blood Service in your state/territory</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10477" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="48723" end="48889" />
        <spannedText>this vaccine is contraindicated in children with encephalopathy of unknown aetiology or with neurologic complications occurring within 7 days following a vaccine dose</spannedText>
        <creationDate>Wed Mar 07 09:26:07 MST 2018</creationDate>
    </annotation>
    <complexSlotMention id="EHOST_Instance_10496">
        <mentionSlot id="has_source" />
        <complexSlotMentionValue value="EHOST_Instance_10478" />
    </complexSlotMention>
    <classMention id="EHOST_Instance_10477">
        <hasSlotMention id="EHOST_Instance_10496" />
        <mentionClass id="claim">this vaccine is contraindicated in children with encephalopathy of unknown aetiology or with neurologic complications occurring within 7 days following a vaccine dose</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10478" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="48669" end="48710" />
        <spannedText>The product information for Infanrix hexa</spannedText>
        <creationDate>Wed Mar 07 09:26:13 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10478">
        <mentionClass id="source_of_claim">The product information for Infanrix hexa</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10479" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="48891" end="48900" />
        <spannedText>The ATAGI</spannedText>
        <creationDate>Wed Mar 07 09:26:16 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10479">
        <mentionClass id="source_of_claim">The ATAGI</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10480" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="48925" end="49033" />
        <spannedText>the only contraindication is a history of anaphylaxis to a previous dose or to any of the vaccine components</spannedText>
        <creationDate>Wed Mar 07 09:26:20 MST 2018</creationDate>
    </annotation>
    <complexSlotMention id="EHOST_Instance_10497">
        <mentionSlot id="has_source" />
        <complexSlotMentionValue value="EHOST_Instance_10479" />
    </complexSlotMention>
    <classMention id="EHOST_Instance_10480">
        <hasSlotMention id="EHOST_Instance_10497" />
        <mentionClass id="claim">the only contraindication is a history of anaphylaxis to a previous dose or to any of the vaccine components</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10481" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="12651" end="12653" />
        <spannedText>39</spannedText>
        <creationDate>Wed Mar 07 09:26:49 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10481">
        <mentionClass id="source_of_claim">39</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10482" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="31043" end="31045" />
        <spannedText>64</spannedText>
        <creationDate>Wed Mar 07 09:27:26 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10482">
        <mentionClass id="source_of_claim">64</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10483" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="34687" end="34689" />
        <spannedText>73</spannedText>
        <creationDate>Wed Mar 07 09:27:38 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10483">
        <mentionClass id="source_of_claim">73</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10484" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="35357" end="35359" />
        <spannedText>62</spannedText>
        <creationDate>Wed Mar 07 09:27:49 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10484">
        <mentionClass id="source_of_claim">62</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10485" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="36906" end="36908" />
        <spannedText>74</spannedText>
        <creationDate>Wed Mar 07 09:27:59 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10485">
        <mentionClass id="source_of_claim">74</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_10486" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="44415" end="44420" />
        <spannedText>92,93</spannedText>
        <creationDate>Wed Mar 07 09:28:28 MST 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_10486">
        <mentionClass id="source_of_claim">92,93</mentionClass>
    </classMention>
    <eHOST_Adjudication_Status version="1.0">
        <Adjudication_Selected_Annotators version="1.0" />
        <Adjudication_Selected_Classes version="1.0" />
        <Adjudication_Others>
            <CHECK_OVERLAPPED_SPANS>false</CHECK_OVERLAPPED_SPANS>
            <CHECK_ATTRIBUTES>false</CHECK_ATTRIBUTES>
            <CHECK_RELATIONSHIP>false</CHECK_RELATIONSHIP>
            <CHECK_CLASS>false</CHECK_CLASS>
            <CHECK_COMMENT>false</CHECK_COMMENT>
        </Adjudication_Others>
    </eHOST_Adjudication_Status>
</annotations>

